Meridian Bioscience (NASDAQ:VIVO) issued its quarterly earnings results on Thursday. The company reported $0.21 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.21, MarketWatch Earnings reports. The firm had revenue of $56.45 million during the quarter, compared to analyst estimates of $55.00 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company posted $0.22 EPS. Meridian Bioscience updated its FY18 guidance to $0.69-0.72 EPS.

VIVO opened at $14.65 on Friday. The firm has a market cap of $607.12, a PE ratio of 21.87 and a beta of 0.96. The company has a debt-to-equity ratio of 0.28, a current ratio of 5.82 and a quick ratio of 3.96. Meridian Bioscience has a fifty-two week low of $13.23 and a fifty-two week high of $16.45.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 17th. Stockholders of record on Monday, May 7th will be paid a dividend of $0.125 per share. This represents a $0.50 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend is Friday, May 4th. Meridian Bioscience’s dividend payout ratio is presently 74.63%.

A number of equities analysts have issued reports on VIVO shares. Zacks Investment Research raised Meridian Bioscience from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Wednesday, March 21st. Canaccord Genuity increased their price target on Meridian Bioscience from $14.00 to $16.00 and gave the company a “hold” rating in a research note on Friday, January 26th. Finally, BidaskClub raised Meridian Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, March 8th.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Earnings History for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with's FREE daily email newsletter.